Somebody paid for him to read that…
https://www.cameo.com/johndelancie
Molnupiravir (MK-4482) Antiviral Description
Molnupiravir (MK-4482, EIDD-2801) is an experimental oral antiviral developed initially to treat influenza at Emory University. Molnupiravir is an orally bioavailable form of a potent ribonucleoside analog that inhibits replicating multiple RNA viruses, including SARS-CoV-2, the causative agent of COVID-19.
https://www.precisionvaccinations.com/vaccines/molnupiravir-mk-4482-antiviral
Molnupiravir was originally developed at Emory University in Georgia by its drug innovation company, Drug Innovation Ventures at Emory. It was later acquired by Ridgeback Biotherapeutics, which has partnered with Merck & Co. to continue developing the antiviral.
Emory University
https://www.emory.edu/home/index.html
Drug Innovation Ventures
http://driveinnovations.org/focus-areas/overview/
Ridgeback Biotherapeutics
https://ridgebackbio.com/